Company Profile
Rallybio Stock Price, News & Analysis
- Ticker:
- RLYB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
16.19 USD (+0.31%)
Close
Last updated: August 6, 2026
94.1M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, RLYB closed up 0.31% at $16.19. No new same-company headline was identified in the current news window.
Company overview
Business overview
Rallybio is a rare-disease biotechnology company focused on complement and immune-mediated disorders. Its pipeline aims at high-unmet-need conditions where targeted biology matters.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Rallybio sits in specialty biotechnology.
Business Model Characteristics
The business depends on clinical proof, pipeline selection, and the ability to create value in rare-disease markets.
Position Within the Biotechnology Landscape
Rallybio is a rare-disease catalyst name whose valuation is closely linked to proof-of-concept and strategy.
Future catalysts
Rallybio’s catalysts are its complement and rare-disease programs, especially whether the company can keep progressing toward a clearer clinical path. The stock tends to respond quickly if the next update shows the platform still has room to run.
Recent news
- 01
- 02
- 03
- 04
Rallybio Announces Reverse Stock Split of Common Stock
Source: Rallybio
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Rallybio (RLYB)?
Rallybio (RLYB) most recently closed at 16.19 USD, a +0.31% move versus the previous session.
What is the market cap of Rallybio (RLYB)?
Rallybio currently has a market capitalization of 94.1M USD on BioPharmSignal.
What does Rallybio do?
Rallybio is a rare-disease biotechnology company focused on complement and immune-mediated disorders. Its pipeline aims at high-unmet-need conditions where targeted biology matters.
On which exchange is RLYB stock listed?
Rallybio (RLYB) is associated with NASDAQ, United States, Biopharma.
What is Rallybio?
Rallybio’s catalysts are its complement and rare-disease programs, especially whether the company can keep progressing toward a clearer clinical path.
Which conditions is Rallybio targeting with Rallybio?
Rallybio’s catalysts are its complement and rare-disease programs, especially whether the company can keep progressing toward a clearer clinical path.
How does Rallybio describe recent progress with Rallybio?
Rallybio’s catalysts are its complement and rare-disease programs, especially whether the company can keep progressing toward a clearer clinical path.
What future catalysts are investors watching for Rallybio?
Rallybio’s catalysts are its complement and rare-disease programs, especially whether the company can keep progressing toward a clearer clinical path. The stock tends to respond quickly if the next update shows the platform still has room to run.